EyePoint Pharmaceuticals Appoints Michael C. Pine as Chief Corporate Development and Strategy Officer

NEXT STORY
Adamis Pharmaceuticals Submits Fast Track Application to FDA for Tempol for the Treatment and Prevention of COVID-19
PREV STORY
Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Tiziana Life Sciences plc: Publication of Research Note

author_avatar
NASDAQ Market News

VBL Therapeutics Receives Milestone Payment From NanoCarrier Under Licensing Agreement for VB-111 in Japan

- Per agreement, milestone payments can exceed $100 million, in addition to double-digit million ...

author_avatar
NASDAQ Market News

Differentiated Approach to Chronic Care Management, “Impact by One Medical,” Designed to Deliver Outsized Results for Patients and Employers within Primary Care

author_avatar
NASDAQ Market News